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Abstract: Schizophrenia and autism spectrum disorder (ASD) are multi-factorial and
multi-symptomatic psychiatric disorders, each affecting 0.5%–1% of the population worldwide.
Both are characterized by impairments in cognitive functions, emotions and behaviour, and they
undermine basic human processes of perception and judgment. Despite decades of extensive research,
the aetiologies of schizophrenia and ASD are still poorly understood and remain a significant
challenge to clinicians and scientists alike. Adding to this unsatisfactory situation, patients with
schizophrenia or ASD often develop a variety of peripheral and systemic disturbances, one prominent
example of which is cancer, which shows a direct (but sometimes inverse) comorbidity in people
affected with schizophrenia and ASD. Cancer is a disease characterized by uncontrolled proliferation
of cells, the molecular origin of which derives from mutations of a cell’s DNA sequence. To counteract
such mutations and repair damaged DNA, cells are equipped with intricate DNA repair pathways.
Oxidative stress, oxidative DNA damage, and deficient repair of oxidative DNA lesions repair
have been proposed to contribute to the development of schizophrenia and ASD. In this article,
we summarize the current evidence of cancer comorbidity in these brain disorders and discuss
the putative roles of oxidative stress, DNA damage and DNA repair in the aetiopathology of
schizophrenia and ASD.
Keywords: DNA base excision repair; XRCC1; neurodevelopmental disorders; oxidative DNA
damage; oxidative stress; autism; schizophrenia; cancer
1. Schizophrenia and Autism Spectrum Disorder: Symptoms and Origins
Schizophrenia and autism spectrum disorder (ASD) are multi-factorial and multi-symptomatic
psychiatric disorders, each affecting 0.5%–1% of the population worldwide [1,2]. Both are characterized
by impairments in cognitive functions, emotions and behaviour, and they undermine basic human
processes of perception and judgment [2,3]. In view of their chronicity and severity, schizophrenia
and ASD impose tremendous mental and economic burdens on the affected individuals, and in turn,
on their families and society in general [4,5].
Typically, the onset of full-blown schizophrenia is in early adulthood and includes a myriad of
symptoms, which are commonly referred to as positive, negative and cognitive symptoms [2]. Positive
symptoms are pathologies that do not present in healthy individuals but are a result of the disease
process. These include visual and/or auditory hallucinations, delusions, paranoia, and psychomotor
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agitation. Negative symptoms refer to physiological features that are reduced or absent as a result of
the disease process, including social withdrawal, apathy, deficits in motivation and reward-related
functions, and alogia. Cognitive symptoms of schizophrenia involve deficits in executive functions,
working memory, and attention, which in turn can undermine reasoning, planning and problem
solving in affected individuals.
ASD is characterized, to a varying degree, by severe deficiencies in social interaction, a
lack of verbal and nonverbal communication, and the presence of restricted and repetitive
behaviours [3]. Initially, ASD was sub-categorized into autism, Asperger syndrome, pervasive
developmental disorder-not otherwise specified (PDD-NOS), and childhood disintegrative
disorder [1,3]. These subtypes seemed to differ primarily in the nature and/or severity of cognitive
delay and the presence of intellectual disability. Individuals with Asperger syndrome generally lack
delays in cognitive development and communication, in contrast to autism. With the release of the 5th
Diagnostic and Statistical Manual of Mental Disorders (DSM-5), however, all subtypes were merged
into one umbrella diagnosis of ASD [6]. Overt symptoms of ASD can begin as early as by the age of six
months, become established by two to three years, and tend to persist throughout life [1,3,7–10].
Interestingly, schizophrenia and ASD seem to overlap at multiple levels. For example,
disruption of emotional processing and sensorimotor gating, and impairments in executive functions,
are psychopathological features commonly observed in both disorders [3,11–16]. Furthermore, patients
with schizophrenia and ASD display a similar pattern of deficient neuronal activation during a
social cognition task, with both patient groups showing reduced activation in the right amygdala,
fusiform gyrus, and ventrolateral prefrontal cortex [17–22]. The impression of overlapping brain
abnormalities between schizophrenia and ASD has also been supported by meta-analytic anatomical
likelihood estimations consolidating multiple imaging datasets, which reveal appreciable brain
structural concordance between the two disorders, especially in the right parahippocampal gyrus,
posterior cingulate, putamen, claustrum and left thalamus [13,17,21,23]. Finally, the neuropathology
of schizophrenia and ASD also overlap at the cellular levels. One example relates to the imbalances
in excitatory versus inhibitory neurotransmission, which involve disturbances in glutamate and
γ-aminobutyric acid (GABA) signalling and leads to increased excitatory-inhibitory ratios in both
disorders [7,8,10,19–21].
Despite decades of extensive research, the aetiologies of schizophrenia and ASD are still poorly
understood and remain a significant challenge to clinicians and scientists alike. According to the
prevailing view, both disorders involve changes in early brain development and subsequent brain
maturation [11,12,14–16,24]. Hence, an interaction between foetal neurodevelopmental disturbances
and changes in postnatal brain maturation seems necessary to trigger the onset of full-blown
psychotic or autistic disorders. Within this neurodevelopmental framework, the combined action
of multiple genes (of small effect size) and a number of environmental risk factors is required to
cause schizophrenia and ASD [17,19–22,25]. According to such gene-environment interaction models,
the effect of an individual’s genotype depends on environmental exposure and, vice versa, the effect
of environmental exposure on risk depends on an individual’s genotype [17,21,23,26,27]. Recent
advances in genome-wide association studies (GWAS) have generated reproducible findings on a
number of common risk alleles in both schizophrenia and ASD [19–21,28,29]. However, the heritability
estimates of the relative contribution of common genetic variants based on molecular genetic data
appear to be considerably smaller [24,30] than heritability estimates from twin studies [25,31,32].
The discrepancy between heritability estimates from twin and molecular genetic studies may emerge
because gene-environment interactions involving shared environmental factors within families
are included in heritability estimates of twin studies, but not in molecular genetic studies of
unrelated subjects [26,27,33]. The comparison between monozygotic and dizygotic twins allows,
to a certain extent, an estimation of the relative contribution of genetic versus environmental factors,
and consequently, twin studies can readily take into account gene-environment interactions in their
heritability estimates. Indeed, it is the general consensus that differences between monozygotic
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twins are primarily attributable to the environment, whereas differences between dizygotic twins
to both hereditary and environmental factors in twin studies [34]. According to several lines of
evidence, however, deducing the contribution of genetic factors in twin studies may be misleading,
partly because the prenatal environment (and its interaction with genetic predisposing factors)
is rarely dealt with adequately [35–37]. For example, the majority of monozygotic twins are
monochorionic. Hence, many monozygotic twins share the same placenta, whereas all dizygotic
twins are dichorionic [38]. Given that normal placental functions are essential for proper foetal
development, including brain development [39], neurodevelopmental abnormalities arising from
placental dysfunctions in monochorionic twins may be misinterpreted as being of genetic origin.
The further elucidation of aetiological mechanisms in schizophrenia and ASD also appears
crucial with regards to the need of more effective treatments. In schizophrenia, pharmacotherapy with
currently available antipsychotic drugs can only partially normalize psychopathological symptoms and
are particularly poor in alleviate negative and cognitive symptoms [28,29,40]. Similarly, there are still
no effective treatments against ASD-related symptoms such as social interaction and communication
deficits [30,41].
Adding to this unsatisfactory situation, patients with schizophrenia or ASD often develop a
variety of peripheral and systemic disturbances, some of which are clinically highly relevant and
can further undermine the daily life quality of the affected individuals [31,32,42,43]. One prominent
example is cancer, which shows a direct (but sometimes inverse) comorbidity in people affected with
neurodevelopmental disorders such as schizophrenia and ASD [33,44–47]. In this article, we summarize
the current evidence of cancer comorbidity in these brain disorders and discuss the putative role of
DNA damage in this context.
2. Schizophrenia, Autism Spectrum Disorder and Cancer Risk
The hypothesis of altered cancer risk in schizophrenia is not new, yet it still appears conflicting,
as reviewed in [40,41]. For example, early studies by Mortensen [42,43,48] showed that the overall
incidence of cancer was lower for male (but not female) patients with schizophrenia as compared to the
general population. A similar reduction in overall cancer risk has also been demonstrated in several
subsequent studies (e.g., [44–47,49,50]. Interestingly, Ji et al. [47,51]) reported that the overall cancer
risk was not only lower in patients, but also significantly reduced among their unaffected parents
and siblings, suggesting the involvement of genetic factors in this association. A similar finding was
provided by Catts et al. [47,52], who found reduced cancer risk in unaffected first-degree relatives of
patient with schizophrenia.
These findings suggesting reduced cancer risk in schizophrenia contrast with other
epidemiological reports demonstrating no changes or even increased risk of developing cancer
in schizophrenia. For example, some reports show increased overall cancer risk in patients with
schizophrenia [48,53,54] or a higher risk for specific cancers such as colon, breast and stomach
cancers [49,50,55,56]. Increased cancer risk was also found in the study by Lin et al., who demonstrated
that this association is restricted to female patients with schizophrenia and inversely correlate with the
age of schizophrenia onset [51,52]. Marked sex differences were also obtained in the study by Ji et al.,
suggesting that female schizophrenic patients have a higher cancer risk than the general population
for breast, cervical and endometrial cancers [47,48].
Hence, the extent to which schizophrenia is associated with altered cancer risk remains
controversial (e.g., reviewed in [33,53,54,57]). One reason for these conflicting findings may be the
varying contribution of environmental factors such as smoking habits, nulliparity, obesity and exposure
to antipsychotics [55,56,58]. Indeed, adjustments for possible confounding factors such as smoking can
markedly change the magnitude or even the direction of cancer risk. For example, Catts et al. found
that schizophrenia is associated with a modest but significant increase in lung cancer risk in unadjusted
analyses [52,59–62]. When adjusted for smoking, however, patients with schizophrenia tend to show
decreased lung cancer risk. Similarly, Lichtermann et al. found that patients with schizophrenia
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display an increased overall cancer risk, whereas cancer risk is consistently lower in their unaffected
first-degree relatives. These diametrically opposite effects may readily be explained by the varying
contribution of specific lifestyle factors such as excessive smoking and alcohol consumption, which are
more prevalent in patients with schizophrenia as compared to non-affected individuals [33,48,57].
In contrast to schizophrenia, only a few studies have estimated cancer risk in ASD. The available
data suggest, however, that ASD is generally associated with increased cancer risk. For example,
ovarian cancers and central nervous system (CNS) cancers such as neurofibromatosis are more
prevalent in ASD subjects as compared to non-ASD subjects [33,57,63]. There is also initial evidence
suggesting that ASD is associated with increased breast cancer risk [58,64]. Interestingly, recent
genome-wide exome sequencing has revealed extensive overlap in risk genes for ASD and for
cancer [59–63], suggesting that altered cancer risk in ASD subjects may have a strong genetic
basis. Many of these genes have been implicated in pathophysiological processes underlying cancer
development, including genes involved in DNA repair [33,57,65]. DNA repair is considered one of
the foremost cellular defence mechanisms to counteract cancer formation, raising the possibility that
changes in DNA repair and/or DNA damage might be a molecular link between altered cancer risk
and neurodevelopmental disorders such as ASD and schizophrenia.
3. DNA Damage, DNA Repair and Cancer
Cancer is a disease characterized by the loss of control by the organism over a small subset of
cells, which start to proliferate regardless of the borders imposed by the surrounding tissue. For this to
occur, cancer cells have to acquire a subset of characteristics that ensures their survival and enables
their growth despite adversary reactions from the surrounding. These features are collectively referred
to as ‘hallmarks of cancer’ [63,66].
The molecular origin of virtually all cancers derives from mutations of a cell’s DNA
sequence [64,67,68]. Indeed, genomic instability and mutation is recognized as one of the very few
enabling characteristics that clearly drive cancer formation by facilitating the acquisition of all other
core hallmarks of cancer [63,65]. Mutations can arise when the integrity of DNA is challenged by agents
deriving from exogenous sources [65]. To counteract the formation of mutations, cells have evolved
a plethora of DNA repair pathways that sense, report and correct alterations in DNA [66,69,70].
Deficiencies in some of these repair pathways have been implicated to act as key players in the
induction and progression of cancer [63,64,67,68]. It is noteworthy, however, that even in the absence
of exposure to damaging exogenous agents (such as ultraviolet (UV) radiation or tobacco smoke), DNA
is a very sensitive molecule prone to undergo spontaneous alterations. These can be caused by DNA’s
chemical instability as well as many different intracellular (endogenous) mutagens that are present
in the cell (reviewed in [65,71]). For instance, the need for oxygen to support all vital functions of a
mammalian cell drives also the formation of a variety of reactive oxygen products, such as hydrogen
peroxide, superoxide ions or hydroxyl radicals. These reactive oxygen species avidly react with
macromolecules present in the cell, among which DNA presents a particularly vulnerable target. DNA
is prone to undergo spontaneous alterations, caused by its chemical instability, as well as the presence
of endogenous harmful agents, such as oxygen radicals (reviewed in [65,68,72–76]). Such insults lead
to the formation of small base lesions and single-strand DNA breaks (SSBs), which are constantly
undermining genomic integrity. Estimates of these lesions range from 10,000–20,000 for small base
lesions up to 150,000 for SSBs generated in every single cell every single day under physiological,
non-stressed conditions [69–71]. If left unrepaired, this type of damage can give rise to the formation of
mutations in the DNA, which can ultimately lead to the onset of diseases such as cancer [63,64,71,76,77].
There are multiple DNA different repair pathways that catalyse the reconstitution of DNA
integrity when it has been compromised. Among them, base excision repair (BER) is one of the most
important mechanisms to safeguard cells from the frequently occurring small DNA base lesions and
SSBs [71,73]. BER acts like a housekeeper that constantly cleans away the multitude of different
base lesions and SSBs, thus ensuring the maintenance of intact and unaltered double-stranded DNA,
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which in turn is pivotal for all physiological cellular functions. Taking into account the numbers of DNA
lesions that BER has to correct even under physiological conditions, it follows that a decrease in BER
repair capacity—either by changes in the protein sequence due to genetic polymorphisms, or changes
in protein expression levels—can lead to an accumulation of DNA damage in the cells. Therefore,
disruptions in DNA repair pathways can cause a change in DNA repair capacity of the affected cell or
tissue that might manifest itself in increased levels of DNA damage. This readily predisposes cells
to accumulating DNA damage, which in turn has been aetiologically linked to the development of a
variety of human diseases, such as cancer, premature aging, and also neurodegenerative conditions
like Alzheimer’s disease and Parkinson’s disease [68,71–76].
Classical BER of damaged DNA bases is initiated by damage-specific DNA glycosylases, which
identify and excise the corrupted base by hydrolysis of the N-glycosylic bond linking the DNA base
to the sugar phosphate backbone (reviewed in [71,76], for details, see Figure 1). The phosphodiester
bond 51 to the resulting abasic site (AP-site) is cleaved by AP endonuclease 1 (APE1), thus generating
a single strand DNA break with 51-deoxyribose phosphate. Importantly, different classes of DNA
glycosylases exist, and they differ in their mechanism to release the damaged base, resulting in a
variety of intermediate products with chemically different termini (for details, see [71,76,77]). All these
repair intermediates containing a variety of termini have to be further processed to yield 31-OH and
51-P residues flanking the 1-nucleotide gap, as these are prerequisite to allow DNA polymerisation and
ligation of the ends. There are several end-processing enzymes in mammalian cells including APE1,
polynucleotide kinase phosphatase (PNKP) and aprataxin, which removes blocking residues from
51- to 31-DNA ends (reviewed in [71,73]). Further processing of this single strand break containing
intermediate is carried out by a DNA repair complex that includes DNA polymerase β (Pol β), X-ray
repair cross-complementation group 1 (XRCC1) and DNA ligase IIIa (Lig III). Pol β has a dRP-lyase
activity that removes the 51-sugar phosphate and also, functioning as a DNA polymerase, adds one
nucleotide to the 31-end of the single-nucleotide gap. Finally, the XRCC1-Lig III complex seals the
DNA ends, therefore accomplishing DNA repair [71,73].
The enzymes of the BER pathway also repair DNA SSBs. SSBs arise from disintegration of
oxidised deoxyribose, yielding a break in the DNA backbone while retaining all DNA bases. Very often,
the termini resulting from such breaks are damaged, and thus need to be processed to give rise to
31-OH and 51-P DNA ends. This processing is performed by a variety of different enzymes, and the
interested reader is referred to an excellent review on this subject [73,83]. After DNA end processing
has been accomplished, the DNA ends are ligated back together by the Polβ/XRCC1/Lig3 complex.
Several mutations in the BER-pathway have been associated with the development of cancer
(reviewed in [78,84]). Most notably, defects in repair of one of the most abundant oxidative DNA lesion,
8-oxo-deoxyGuanine (8-oxo-G), are implicated in familial cancer syndromes involving mutations
in the DNA glycosylases MutY homolog (MUTYH) or 8-oxoguanine DNA-glycosylase 1 (Ogg1).
8-oxo-G is a miscoding lesion that can lead to insertion of incorrect A opposite 8-oxo-G upon DNA
replication, which therefore frequently leads to formation of an A:8-oxo-G base pair during DNA
replication (reviewed in [79,85]). If left unrepaired, this mismatch can further propagate into a CGÑAT
transversion point mutation upon further replication. MUTYH is a DNA glycosylase that removes the A
from A:8-oxo-G base pairs, thus paving the way for correction of the 8-oxo-G damage by a coordinated
interplay of DNA polymerase λ, Ogg1 DNA glycosylase and the canonical BER pathway [80–82,86–88].
As mentioned above, cancer is a disease characterized by uncontrolled proliferation of cells.
In view of the fact that ASD and schizophrenia are manifestations of neuronal cell dysfunction, how can
a defect in a single gene possibly cause neuronal dysfunction—which per se is not characterized with
increased cellular proliferation, as neuronal cells are postmitotic—while at the same time causing
an defect in another tissue that gives rise to cancer? In an attempt to answer this, consider the
following examples.
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is performed by a variety of end-processing enzymes. This processing results in the generation of a 
3′-OH and a 5′-P group adjacent to the DNA gap or break; (B) Single-strand breaks (SSBs) can also 
arise from direct disintegration of oxidised deoxyribose. This process usually leads to damaged or 
modified termini, which are processed by a variety of enzymes to 3′-OH and 5′-P groups. SSBs are 
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that includes DNA polymerase β (Pol β), XRCC1 (X-ray repair cross-complementation group 1) and 
DNA ligase IIIa (Lig III). Pol β possesses a dRP-lyase activity that removes the 5′-sugar phosphate 
and also, functioning as a DNA polymerase, adds one nucleotide to the 3′-end of the arising  
single-nucleotide gap. Finally, the XRCC1-Lig III complex seals the DNA ends, therefore 
accomplishing complete DNA repair [71,80–82]. 
Figure 1. Simplified scheme of base exc sion re (BER). Modified after [76,78]. (A) BER is initiated
by damage-specific DNA glycosylases, which identify and release the corrupted base by hydrolysis of
the N-glycosylic bond linking the DNA base to the sugar phosphate backbone (reviewed in [76,79]).
The arising abasic (AP) site is further processed by AP-endonuclease 1 (APE1), and depending on the
mechanism by which the DNA base was removed, end processing of the modified 31- and 51-termini
is performed by a variety of end-processing enzymes. This processing results in the generatio of a
31-OH and a 51-P group adjacent to the DNA gap or break; (B) Single-strand breaks (SSBs) can also
arise from direct disintegration of oxidised deoxyribose. This process usually leads to damaged or
modified termini, which are processed by a variety of enzymes to 31-OH and 51-P groups. SSBs are then
handled identically to the BER intermediates from this point onward; (C) Further processing of the
SSB containing intermediate stemming from either source is carried out by the core BER complex that
inclu es DNA po merase β (Pol β), XRCC1 (X-ray epair cross-complementation group 1) and DNA
ligase IIIa (Lig III). Pol β possesses a dRP-lyase activity that removes the 51-sugar phosphate and also,
functioning as a DNA polymerase, adds one nucleotide to the 31-end of the arising single-nucleotide
gap. Finally, the XRCC1-Lig III complex seals the DNA ends, therefore accomplishing complete
DNA repair [71,80–82].
Several genetic disorders demonstrate that changes in a single protein can have a multifaceted
i act o the entir organism. Among the most prominent examples to illustrate that a defect in one
gene product gives rise simultaneously to a variety of neurological as well as oncological disorders is
Ataxia-Teleangiectasia (A-T). A-T is a rare autosomal recessive disorder caused by mutation of the gene
A-T mutated (ATM), a serine-threonine protein kinase that orchestrates the response to cellular stress
situations, such as DNA double-strand breaks (reviewed in [83]). A-T patients develop early-onset
progressive cerebellar ataxia, oculocutaneous teleangiectasia, immunodeficiency, and have a high
incidence of cancer, particularly lymphoid tumours. One of the main questions arising from these
findings is, how can a gene defect cause cellular dysfunction in one tissue, while being accessory to the
development of a proliferative malignancy in others? The main reason for this variegated phenotype is
most likely based on cellular differences in the affected tissues, namely postmitotic neurons in the brain
versus proliferative cells from the hematopoietic lineage in the case of lymphoid tumours. While genetic
instability in postmitotic cells such as the brain manifest in cellular dysfunction, which then leads
to clinical features of neurodegeneration due to the loss of neuronal tissue, in a cell with replicative
potential it can lead to malignant transformation thus giving rise to cancer. Another very interesting
example for how a decrease in neuronal function can be associated at the same time with an increased
cancer risk are patients with Down syndrome (DS). In DS patients chromosome 21, or parts thereof,
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is present in triplicate, which clinically manifests in physical growth delays, intellectual disability, and
a series of other disorders (reviewed in [84]). Moreover, DS patients exhibit a 10- to 20-fold higher
risk for leukemia but markedly lower incidence of solid tumours (reviewed in [85]). The molecular
basis behind these differences in cancer predisposition remain unclear to date, but the cell-type specific
effect that is alluded to above could very well play an important determinant in the case of DS as well.
4. Oxidative Stress, DNA Damage and DNA Repair in Schizophrenia and Autism
Spectrum Disorder
4.1. Oxidative Stress, Mitochondrial Dysfunctions and DNA Damage
As outlined above, DNA damage can either stem from exposure to exogenous DNA damaging
agents, such as tobacco smoke or UV radiation, endogenous sources such as oxidative stress stemming
from the respiratory chain, or it can be caused by a decrease in repair of normal levels of DNA
damage constantly present in our genomes. Within the last decades, a plethora of findings have
implicated oxidative stress and subsequent DNA damage in the development of schizophrenia and
ASD. Indeed, signs of increased oxidative stress and oxidative DNA damage has been detected in
various tissues of schizophrenic patients [86–107]. Additional evidence supporting a role of redox
imbalances and oxidative stress in the development of schizophrenia stems from various animal
models, which suggest that increased oxidative stress during sensitive windows of brain development
and maturation is causally related to the subsequent emergence of schizophrenia-related brain and
behavioral abnormalities [108–112].
Redox imbalances and oxidative stress in schizophrenia may further involve, or even be triggered
by, functional deficits in the mitochondrial respiratory chain (reviewed in [108,113]). In support of this
hypothesis, mitochondrial dysfunctions have been closely linked to the pathogenesis of schizophrenia
and related psychotic disorders (reviewed in [89,90,114,115]). It still remains debatable, however,
whether increased oxidative stress is the primary cause or rather a consequence of mitochondrial
deficits. According to recent theories [91,93,95,116], oxidative stress may not be primarily involved
in generating mitochondrial DNA damage, but rather triggers a cellular stress response that in turn
causes damage. It is also known that deletions in mitochondrial DNA increase as a function of
age, especially in post-mitotic cells with high metabolic demands, such as the brain. Interestingly,
however, post-mortem analyses of mitochondrial deletions revealed a significant decrease in the global
accumulation of mitochondrial DNA deletions in patients with schizophrenia as compared to patients
with major depressive disorder or bipolar, or compared to age-matched control subjects [108,117].
This decrease was largest in dopaminergic regions such as caudate nucleus, putamen and substantia
nigra [108,118]. One interpretation of these findings is that schizophrenia is, for yet unknown reasons,
associated with a primary deficit in mitochondrial functions, which in turn might lead to a decrease in
mitochondrial metabolism and therefore result in reduced mitochondrial deletions.
Increased levels of oxidative stress and oxidative DNA damage have also been reported in ASD
subjects, as well as in animal models relevant to this disorder [114,115,119]. Reduced ratios of reduced
glutathione (GSH) to its oxidised form GSSG (glutathione disulfide), indicative of oxidative stress,
along with decreased total GSH levels were found in the cerebellum and temporal cortex in ASD
subjects, suggesting a deficit in the redox balancing system and the antioxidant defence mechanisms
in affected individuals [116,120]. Decreased GSH:GSSG ratios along with increased levels of 8-oxo-G
and other markers of oxidative stress were also detected in the cerebellum and Brodmann Area 22 of
ASD subjects [117,121–123]. Moreover, oxidation damage to DNA and a deficit in antioxidant capacity
was also found in plasma from children with ASD as compared to non-affected siblings [114,118,124].
Similar to schizophrenia, functional deficits in the mitochondrial respiratory chain may readily
contribute to the emergence of increased oxidative stress in ASD. In support of this hypothesis,
Napoli et al. found higher frequencies of deletions and small base transitions in the mitochondrial
DNA obtained from ASD children [119,125]. Signs of deficient mitochondrial functions in ASD subjects
are also apparent in post-mortem brain samples. For example, Tang et al. revealed altered levels of
Int. J. Mol. Sci. 2016, 17, 856 8 of 17
proteins involved in the mitochondrial respiratory chain, decreased activity of the respiratory chain,
decreased antioxidant levels, as well as more oxidative DNA damage in post-mortem brains of patients
affected with ASD [120,126].
4.2. Dysregulated DNA Repair and DNA Damage
Insufficiency in DNA repair is an alternative (but not mutually exclusive) mechanism that can
precipitate DNA damage in general, and in neurodevelopmental disorders such as schizophrenia and
autism in particular. Indeed, several studies have linked polymorphisms in DNA repair genes to the
development of schizophrenia and ASD. Intriguingly, genetic polymorphisms in the core BER-protein
XRCC1 itself, or in XRCC1 interacting proteins such as Ogg1, have been repeatedly implicated in
schizophrenia [121–123,127] and ASD [114,124,128]. The mRNA levels of the DNA glycosylase MBD4
and Ape1 were also reported to be upregulated in the brains of patients with schizophrenia and
related disorders [42,43,51,125], adding further evidence for the hypothesis of altered DNA repair in
psychotic disorders.
In an effort to assess the cellular capacity for DNA repair in schizophrenia patients, several
attempts have been made to measure DNA damage under basal conditions and in response to
cellular stressors. Quantification of DNA repair through measurements of unscheduled DNA
synthesis in response to methyl methanesulfonate (MMS), methylnitronitrosoguanine (MNNG) and UV
radiation [126,129], or through the Comet assay after H2O2 treatment or γ-irradiation [127,130], failed to
detect any significant differences between cells obtained from patients with schizophrenia and controls.
Young et al. reported similar results, yet they found higher levels of DNA damage in male compared
to female patients [128,131]. The latter results emphasize the importance of assessing phenotypes
in a gender-specific manner, similarly to what has been proposed for epidemiologic investigations
assessing cancer incidence in schizophrenia (e.g., [42,43,51,132]). Flow cytometric analysis of the
DNA double-strand break marker γH2AX in immortalized lymphoblasts from schizophrenia patients
revealed a significantly higher baseline levels of γH2AX in untreated cells, and a reduced γH2AX
response upon irradiation with 5 Gray [63,64,67,68,129]. Higher baseline levels of γH2AX in untreated
cells may mirror pre-existing DNA damage as a result of increased oxidative stress and/or replication
stress, whereas a failure to mount sufficient γH2AX responses may point towards an aberration of
the DNA damage response involving γH2AX formation in lymphoblasts from schizophrenic patients.
It should be noted, however, that γH2AX is only a surrogate marker for cellular stress responses but
does not index DNA damage per se. Hence, the extent to which these findings may reflect actual
differences in DNA repair still awaits verification.
Attempts to explore DNA repair mechanisms in ASD are limited to a few investigations and
have thus far provided equivocal results. For example, cytogenetic analyses of chromosome fragile
sites initially revealed significant differences in chromosome lesions in ASD patients relative to
controls [130,133]. In contrast, a comparison between lymphocytes from ASD children, unaffected
siblings and community controls showed no signs for genomic instability using the cytokinesis-block
micronucleus assay (CBMA) [76,131]. While the latter assay allows detection of gross molecular events
like chromosome breakage, loss or rearrangement, it is unable to detect more subtle changes in DNA
structure and repair. Therefore, these findings leave the question unanswered as to whether ASD
patients may display more subtle damage to DNA or not. Comparing lymphoblasts from ASD children
and their siblings, Main et al. further found an increased sensitivity of ASD samples to necrosis caused
by oxidative stress. At the same time, the authors revealed no difference in DNA damage using the
CBMA assay [132,133], suggesting that ASD patients do not display gross abnormalities in DNA
structure and repair.
Taken together, there is accumulating evidence supporting a role of increased oxidative stress
and impaired mitochondrial functions in schizophrenia and ASD. However, the available data are
inconclusive, so that additional research will be needed to ascertain whether or not DNA repair
mechanisms are altered in these disorders. Whilst genetic linkage studies readily support this
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hypothesis, the nature and/or severity of abnormal DNA repair and damage in schizophrenia and
ASD await further exploration.
5. DNA Repair and Damage in Schizophrenia and Autism: A Role beyond Altered Cancer Risk?
In view of the crucial roles of genomic stability and DNA repair in cancer [63,64,67,68,133],
it appears plausible that altered expression of DNA repair genes and/or functional impairments
in DNA repair mechanisms may contribute to altered cancer risk in schizophrenia and autism.
Exploring this putative relationship clearly warrants future investigation as it may help advance
our understanding of why certain types of cancers are more prevalent in patients with schizophrenia
or ASD, whereas others seem to be less common in these neurodevelopmental disorders (see Section 2).
Another burning question in this context is whether altered DNA repair and/or DNA damage
may play an aetiopathological role beyond cancer risk. Or in other words: is there a pathological
connection between altered DNA repair pathways and abnormal brain development relevant to the
neurodevelopmental origins of schizophrenia and ASD?
Experimental work in animal models has recently begun examining this question. Bjørge et al.
used a mouse model, in which the expression of the two DNA glycosylases Ogg1 and MUTYH was
genetically ablated [133,134]. As discussed above, Ogg1 and MUTYH are both involved in the removal
of the oxidative DNA lesion 8-oxo-G, so that their ablation are expected to increase DNA damage
in dividing cells [76]. The authors found that loss of both these glycosylases induced a synergistic
effect on anxiety-like behaviour [133,135–137]. Transcriptomic analysis of the hippocampi of these
mice revealed a possible role of the two glycosylases in hippocampal gene expression, which related
primarily to mal-adaptive behaviour. However, Ogg1 and MUTYH double-knockout animals did not
display overt changes in 8-oxo-G levels in any of the brain tissue analysed [133,138], making it difficult
to attribute the observed behavioural and transcriptional changes to DNA damage. An alternative
(and more likely) explanation for the behavioural induced by Ogg1 and MUTYH ablation is that the
genetic manipulation interfered with transcription independently of 8-oxo-G processing in the brain.
Furthermore, the lack of 8-oxo-G accumulation following Ogg1 and MUTYH could be the result of
redundancies in pathways catalysing its removal, an effect that may be particularly pronounced in the
CNS due to the postmitotic nature of brain cells.
Selected deficits in learning and memory have also been observed in mice deficient of other DNA
glycosylases, including Neil1 and Neil3 [134,139] and reviewed in [76,140]. Even though the relative
contribution of altered DNA repair and DNA damage remains elusive in these models, these findings
indicate that the loss of these DNA glycosylases exerts a long-lasting impact on cognitive functions.
Based on these promising findings, extending the phenotypes of Neil1 and Neil3 ablation to other
behavioural and cognitive functions relevant to schizophrenia and ASD, including social interaction,
central information processing and filtering, sustained and selective attention, and working memory,
seems highly warranted [135–137,141].
Long-lasting neural defects have also been identified in mice with genetic XRCC1 deficiency [138].
A reduction of XRCC1 levels leads to a decrease in the overall BER capacity of a cell, primarily
because Pol β and Lig III are unstable in the absence of XRCC1 as scaffolding protein [139,142,143].
This leads to the accumulation of endogenous SSBs in primary cells, even in the absence of exogenously
administered DNA damaging agents, as endogenously arising lesions are not repaired properly
and in time [140]. The complete knockout of XRCC1 is embryonically lethal, possibly because of
a failure to repair DNA breaks arising during embryonic development [141]. To circumvent this
problem, Lee et al. (2009) developed an XRCC1-loxP mouse that allows a conditional ablation
of XRCC1 in specific tissues when crossed with the appropriate Cre-driver mouse expressing the
cre-recombinase in the tissue of interest [138]. Using this approach, they showed that Nes-Cre driven
ablation of XRCC1 in the CNS leads to impaired development of the cerebellum and hippocampus,
two brain regions strongly implicated in neurodevelopmental disorders such as schizophrenia and
ASD [142,143]. These abnormalities seemed to arise from a persistent accumulation of single-strand
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strand breaks in mature neuronal populations and markedly affect γ-aminobutyric acid (GABA)
interneurons [138]. The latter effects are of particular interest because cellular abnormalities in
GABAergic circuitries are hallmark neuropathological features of neurodevelopmental brain disorders
such as schizophrenia and autism [144,145]. GABAergic interneurons critically regulate neuronal
oscillatory activity [146], which in turn is believed to serve various complex functions, including
perception, cognition, and memory [147]. Hence, impairments in GABAergic functions resulting
from genetic XRCC1 deficiency may cause a spectrum of behavioural and cognitive deficits that are
reminiscent of functional deteriorations in developmental neuropsychiatric disorders. Whether DNA
damage is directly involved in the aetiopathology of schizophrenia and ASD, however, still awaits
direct examination.
6. Conclusions and Perspectives
To summarize, direct experimental evidence for the hypothesis that DNA damage and/or
genetic disruptions of DNA repair genes can causally contribute to the onset of schizophrenia
and ASD is slowly growing. Nevertheless, whether DNA damage and DNA repair is causally
connected to ASD and schizophrenia remains controversial. Indeed, the current status of research
is still far from rendering even a rudimentary picture of all the possible mechanisms involved,
or understanding how, and in which phase, which particular source of DNA damage leads to
alterations relevant to schizophrenia and autism. Here, it will be highly interesting and important
also to dissect the contribution of the DNA damaging insult occurring during prenatal development
versus damage incurred throughout adolescence or adulthood. Furthermore, it remains completely
unclear how DNA damage mechanistically drives cellular changes that drive the observed phenotype
in these disorders. Another salient feature in respect to patient-based epidemiological studies is the
observation of gender-specific differences pertaining to certain traits, as seen for cancer incidence
reports. Future research—not only in this field, but also in other biomedical research—will probably
have to address these gender-specific variations more thoroughly when assessing phenotypes, both in
epidemiological as well as in basic research settings. Detailed analysis of all these aspects warrants
future investigations to broaden our understanding of the underlying mechanisms, and has the
potential to spark development of novel therapeutic approaches to cure, or at least alleviate the
severity, of neurodevelopmental diseases.
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